BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Goldblatt D, Southern J, Andrews N, Ashton L, Burbidge P, Woodgate S, Pebody R, Miller E. The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50-80 years. Clin Infect Dis. 2009;49:1318-1325. [PMID: 19814624 DOI: 10.1086/606046] [Cited by in Crossref: 108] [Cited by in F6Publishing: 106] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Buchwald UK, Andrews CP, Ervin J, Peterson JT, Tamms GM, Krupa D, Ajiboye P, Roalfe L, Krick AL, Sterling TM, Wang M, Martin JC, Stek JE, Kohn MA, Folaranmi T, Abeygunawardana C, Hartzel J, Musey LK; V110–029 Study Group. Sequential administration of Prevnar 13™ and PNEUMOVAX™ 23 in healthy participants 50 years of age and older. Hum Vaccin Immunother 2021;:1-13. [PMID: 34019468 DOI: 10.1080/21645515.2021.1888621] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Schmoele-Thoma B, van Cleeff M, Greenberg RN, Gurtman A, Jones TR, Sundaraiyer V, Gruber WC, Scott DA. Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults. Hum Vaccin Immunother 2019;15:575-83. [PMID: 30648932 DOI: 10.1080/21645515.2018.1538618] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Jackson LA, Gurtman A, van Cleeff M, Jansen KU, Jayawardene D, Devlin C, Scott DA, Emini EA, Gruber WC, Schmoele-thoma B. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. Vaccine 2013;31:3577-84. [DOI: 10.1016/j.vaccine.2013.04.085] [Cited by in Crossref: 150] [Cited by in F6Publishing: 127] [Article Influence: 18.8] [Reference Citation Analysis]
4 Ermlich SJ, Andrews CP, Folkerth S, Rupp R, Greenberg D, McFetridge RD, Hartzel J, Marchese RD, Stek JE, Abeygunawardana C, Musey LK. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults ≥50 years of age. Vaccine 2018;36:6875-82. [PMID: 29559167 DOI: 10.1016/j.vaccine.2018.03.012] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
5 Phipps JP, Haas KM. An Adjuvant That Increases Protective Antibody Responses to Polysaccharide Antigens and Enables Recall Responses. J Infect Dis 2019;219:323-34. [PMID: 30289460 DOI: 10.1093/infdis/jiy506] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
6 Gladstone RA, Jefferies JM, Faust SN, Clarke SC. Pneumococcal 13-valent conjugate vaccine for the prevention of invasive pneumococcal disease in children and adults. Expert Rev Vaccines 2012;11:889-902. [PMID: 23002969 DOI: 10.1586/erv.12.68] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
7 Tromp KM, Campbell MW, Vazquez A. Recent Developments and Future Directions of Pneumococcal Vaccine Recommendations. Clin Ther 2015;37:928-34. [PMID: 25913921 DOI: 10.1016/j.clinthera.2015.03.025] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
8 Giefing-Kröll C, Berger P, Lepperdinger G, Grubeck-Loebenstein B. How sex and age affect immune responses, susceptibility to infections, and response to vaccination. Aging Cell 2015;14:309-21. [PMID: 25720438 DOI: 10.1111/acel.12326] [Cited by in Crossref: 312] [Cited by in F6Publishing: 270] [Article Influence: 52.0] [Reference Citation Analysis]
9 Spurrier MA, Jennings-Gee JE, Daly CA, Haas KM. The PD-1 Regulatory Axis Inhibits T Cell-Independent B Cell Memory Generation and Reactivation. J Immunol 2021;207:1978-89. [PMID: 34535576 DOI: 10.4049/jimmunol.2100336] [Reference Citation Analysis]
10 Lode H, Schmoele-thoma B, Gruber W, Ahlers N, Fernsten P, Baker S, Razmpour A, Siber G, Hackell J, Lockhart S, Burkhardt O, Welte T, de Roux A. Dose-ranging study of a single injection of pneumococcal conjugate vaccine (1×, 2×, or 4×) in healthy subjects aged 70 years or older. Vaccine 2011;29:4940-6. [DOI: 10.1016/j.vaccine.2011.04.132] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
11 Rozenbaum MH, Hak E, van der Werf TS, Postma MJ. Results of a cohort model analysis of the cost-effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged > or =65 years in the Netherlands. Clin Ther 2010;32:1517-32. [PMID: 20728764 DOI: 10.1016/j.clinthera.2010.06.016] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 3.4] [Reference Citation Analysis]
12 Meerveld-Eggink A, de Weerdt O, de Voer RM, Berbers GA, van Velzen-Blad H, Vlaminckx BJ, Biesma DH, Rijkers GT. Impaired antibody response to conjugated meningococcal serogroup C vaccine in asplenic patients. Eur J Clin Microbiol Infect Dis 2011;30:611-8. [PMID: 21184126 DOI: 10.1007/s10096-010-1129-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
13 Weinberg A, Lambert SL, Canniff J, Yu L, Lang N, Esser MT, Falloon J, Levin MJ. Antibody and B cell responses to an investigational adjuvanted RSV vaccine for older adults. Hum Vaccin Immunother 2019;15:2466-74. [PMID: 30852939 DOI: 10.1080/21645515.2019.1589282] [Reference Citation Analysis]
14 Musher DM, Sampath R, Rodriguez-Barradas MC. The potential role for protein-conjugate pneumococcal vaccine in adults: what is the supporting evidence? Clin Infect Dis 2011;52:633-40. [PMID: 21292668 DOI: 10.1093/cid/ciq207] [Cited by in Crossref: 58] [Cited by in F6Publishing: 55] [Article Influence: 5.8] [Reference Citation Analysis]
15 Jackson LA. Pneumococcal polysaccharide vaccines. Vaccines. Elsevier; 2013. pp. 542-72. [DOI: 10.1016/b978-1-4557-0090-5.00033-1] [Cited by in Crossref: 4] [Article Influence: 0.5] [Reference Citation Analysis]
16 Hoffman TW, van Kessel DA, Rijkers GT. Impact of Using Different Response Criteria for Pneumococcal Polysaccharide Vaccination for Assessment of Humoral Immune Status. J Clin Immunol 2018;38:149-52. [DOI: 10.1007/s10875-017-0470-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
17 Quach-Thanh C, Thomas MH; approved by NACI. Statement on the Use of Conjugate Pneumococcal Vaccine - 13 Valent in Adults (Pneu-C-13): An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI). Can Commun Dis Rep 2013;39:1-52. [PMID: 31682649 DOI: 10.14745/ccdr.v39i00a05] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
18 Klugman KP, Dagan R, Malley R, Whitney CG. Pneumococcal Conjugate Vaccine and Pneumococcal Common Protein Vaccines. Plotkin's Vaccines. Elsevier; 2018. pp. 773-815.e18. [DOI: 10.1016/b978-0-323-35761-6.00045-6] [Cited by in Crossref: 5] [Article Influence: 1.7] [Reference Citation Analysis]
19 Scelfo C, Menzella F, Fontana M, Ghidoni G, Galeone C, Facciolongo NC. Pneumonia and Invasive Pneumococcal Diseases: The Role of Pneumococcal Conjugate Vaccine in the Era of Multi-Drug Resistance. Vaccines (Basel) 2021;9:420. [PMID: 33922273 DOI: 10.3390/vaccines9050420] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Fedson DS, Nicolas-Spony L, Klemets P, van der Linden M, Marques A, Salleras L, Samson SI. Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe. Expert Rev Vaccines 2011;10:1143-67. [PMID: 21810065 DOI: 10.1586/erv.11.99] [Cited by in Crossref: 79] [Cited by in F6Publishing: 70] [Article Influence: 7.9] [Reference Citation Analysis]
21 Zimmermann P, Curtis N. Factors That Influence the Immune Response to Vaccination. Clin Microbiol Rev. 2019;32. [PMID: 30867162 DOI: 10.1128/cmr.00084-18] [Cited by in Crossref: 132] [Cited by in F6Publishing: 68] [Article Influence: 66.0] [Reference Citation Analysis]
22 Kong Y, Zhang W, Jiang Z, Wang L, Li C, Li Y, Xia J. Immunogenicity and safety of a 23-valent pneumococcal polysaccharide vaccine in Chinese healthy population aged >2 years: A randomized, double-blinded, active control, phase III trial. Hum Vaccin Immunother 2015;11:2425-33. [PMID: 26083953 DOI: 10.1080/21645515.2015.1055429] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
23 Tobudic S, Plunger V, Sunder-Plassmann G, Riegersperger M, Burgmann H. Randomized, single blind, controlled trial to evaluate the prime-boost strategy for pneumococcal vaccination in renal transplant recipients. PLoS One. 2012;7:e46133. [PMID: 23029408 DOI: 10.1371/journal.pone.0046133] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 3.8] [Reference Citation Analysis]
24 Frenck RW, Yeh S. The development of 13-valent pneumococcal conjugate vaccine and its possible use in adults. Expert Opinion on Biological Therapy 2011;12:63-77. [DOI: 10.1517/14712598.2012.636348] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
25 Baxendale HE, Keating SM, Johnson M, Southern J, Miller E, Goldblatt D. The early kinetics of circulating pneumococcal-specific memory B cells following pneumococcal conjugate and plain polysaccharide vaccines in the elderly. Vaccine 2010;28:4763-70. [PMID: 20471437 DOI: 10.1016/j.vaccine.2010.04.103] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 2.9] [Reference Citation Analysis]
26 Tashani M, Alfelali M, Barasheed O, Alqahtani AS, Heron L, Wong M, Rashid H, Booy R. Effect of Tdap when administered before, with or after the 13-valent pneumococcal conjugate vaccine (coadministered with the quadrivalent meningococcal conjugate vaccine) in adults: A randomised controlled trial. Vaccine 2016;34:5929-37. [PMID: 27780630 DOI: 10.1016/j.vaccine.2016.10.020] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
27 Vila-Corcoles A, Ochoa-Gondar O. Pneumococcal vaccination among adults with chronic respiratory diseases: a historical overview. Expert Rev Vaccines 2012;11:221-36. [PMID: 22309670 DOI: 10.1586/erv.11.176] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
28 Fedson DS, Guppy MJ. Pneumococcal vaccination of older adults: conjugate or polysaccharide? Hum Vaccin Immunother 2013;9:1382-4. [PMID: 23732892 DOI: 10.4161/hv.24692] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
29 Norton NB, Stanek RJ, Mufson MA. Routine pneumococcal vaccination of children provokes new patterns of serotypes causing invasive pneumococcal disease in adults and children. Am J Med Sci 2013;345:112-20. [PMID: 22814362 DOI: 10.1097/MAJ.0b013e3182517785] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.9] [Reference Citation Analysis]
30 De La Rosa I, Munjal IM, Rodriguez-Barradas M, Yu X, Pirofski LA, Mendoza D. Protease Inhibitors Do Not Affect Antibody Responses to Pneumococcal Vaccination. Clin Vaccine Immunol 2016;23:524-9. [PMID: 27074938 DOI: 10.1128/CVI.00026-16] [Reference Citation Analysis]
31 Blanchard-Rohner G, Enriquez N, Lemaître B, Cadau G, Giostra E, Hadaya K, Meyer P, Gasche-Soccal PM, Berney T, van Delden C, Siegrist CA. Pneumococcal immunity and PCV13 vaccine response in SOT-candidates and recipients. Vaccine 2021;39:3459-66. [PMID: 34023135 DOI: 10.1016/j.vaccine.2021.05.030] [Reference Citation Analysis]
32 Laratta CR, Williams K, Vethanayagam D, Ulanova M, Vliagoftis H. A case series evaluating the serological response of adult asthma patients to the 23-valent pneumococcal polysaccharide vaccine. Allergy Asthma Clin Immunol 2017;13:27. [PMID: 28596792 DOI: 10.1186/s13223-017-0200-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
33 Karlsson J, Hogevik H, Andersson K, Roshani L, Andréasson B, Wennerås C. Pneumococcal vaccine responses in elderly patients with multiple myeloma, Waldenstrom’s macroglobulinemia, and monoclonal gammopathy of undetermined significance. Trials in Vaccinology 2013;2:31-8. [DOI: 10.1016/j.trivac.2013.09.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
34 Greenberg RN, Gurtman A, Frenck RW, Strout C, Jansen KU, Trammel J, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60-64 years of age. Vaccine 2014;32:2364-74. [PMID: 24606865 DOI: 10.1016/j.vaccine.2014.02.002] [Cited by in Crossref: 100] [Cited by in F6Publishing: 79] [Article Influence: 14.3] [Reference Citation Analysis]
35 Fedson DS. Pneumococcal conjugate vaccination for older adults: Reply letter to Hollingsworth et al. Hum Vaccin Immunother 2014;10:47-51. [PMID: 24030320 DOI: 10.4161/hv.26422] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
36 Dransfield MT, Harnden S, Burton RL, Albert RK, Bailey WC, Casaburi R, Connett J, Cooper JA, Criner GJ, Curtis JL, Han MK, Make B, Marchetti N, Martinez FJ, McEvoy C, Nahm MH, Niewoehner DE, Porszasz J, Reilly J, Scanlon PD, Scharf SM, Sciurba FC, Washko GR, Woodruff PG, Lazarus SC; NIH COPD Clinical Research Network. Long-term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease. Clin Infect Dis 2012;55:e35-44. [PMID: 22652582 DOI: 10.1093/cid/cis513] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 4.0] [Reference Citation Analysis]
37 Mitchell R, Trück J, Pollard AJ. Use of the 13-valent pneumococcal conjugate vaccine in children and adolescents aged 6 - 17 years. Expert Opin Biol Ther 2013;13:1451-65. [PMID: 23889554 DOI: 10.1517/14712598.2013.824419] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
38 Andrews NJ, Waight PA, George RC, Slack MP, Miller E. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. Vaccine 2012;30:6802-8. [PMID: 23000122 DOI: 10.1016/j.vaccine.2012.09.019] [Cited by in Crossref: 150] [Cited by in F6Publishing: 128] [Article Influence: 16.7] [Reference Citation Analysis]
39 Haas KM, Blevins MW, High KP, Pang B, Swords WE, Yammani RD. Aging promotes B-1b cell responses to native, but not protein-conjugated, pneumococcal polysaccharides: implications for vaccine protection in older adults. J Infect Dis 2014;209:87-97. [PMID: 23964109 DOI: 10.1093/infdis/jit442] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
40 Rodenburg GD, van Gils EJ, Veenhoven RH, Bogaert D, van den Dobbelsteen GP, Berbers GA, Sanders EA. Lower immunoglobulin G antibody responses to pneumococcal conjugate vaccination at the age of 2 years after previous nasopharyngeal carriage of Streptococcus pneumoniae. J Pediatr 2011;159:965-70.e1. [PMID: 21813135 DOI: 10.1016/j.jpeds.2011.06.011] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
41 Ben-David D, Schwaber MJ, Adler A, Masarwa S, Edgar R, Navon-Venezia S, Schwartz D, Porat N, Kotlovsky T, Polivkin N, Weinberg I, Lazary A, Ohana N, Dagan R. Persistence and complex evolution of fluoroquinolone-resistant Streptococcus pneumoniae clone. Emerg Infect Dis 2014;20:799-805. [PMID: 24751142 DOI: 10.3201/eid2005.130142] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
42 Jiang Y, Gauthier A, Annemans L, van der Linden M, Nicolas-Spony L, Bresse X. Cost-effectiveness of vaccinating adults with the 23-valent pneumococcal polysaccharide vaccine (PPV23) in Germany. Expert Rev Pharmacoecon Outcomes Res 2012;12:645-60. [PMID: 23025422 DOI: 10.1586/erp.12.54] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
43 Namkoong H, Funatsu Y, Oishi K, Akeda Y, Hiraoka R, Takeshita K, Asami T, Yagi K, Kimizuka Y, Ishii M, Tasaka S, Suzuki Y, Iwata S, Betsuyaku T, Hasegawa N. Comparison of the immunogenicity and safety of polysaccharide and protein-conjugated pneumococcal vaccines among the elderly aged 80 years or older in Japan: an open-labeled randomized study. Vaccine 2015;33:327-32. [PMID: 25448102 DOI: 10.1016/j.vaccine.2014.11.023] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
44 Huang SS, Johnson KM, Ray GT, Wroe P, Lieu TA, Moore MR, Zell ER, Linder JA, Grijalva CG, Metlay JP, Finkelstein JA. Healthcare utilization and cost of pneumococcal disease in the United States. Vaccine 2011;29:3398-412. [DOI: 10.1016/j.vaccine.2011.02.088] [Cited by in Crossref: 178] [Cited by in F6Publishing: 169] [Article Influence: 17.8] [Reference Citation Analysis]
45 Meena J, Kumar R, Singh M, Ahmed A, Panda AK. Modulation of immune response and enhanced clearance of Salmonella typhi by delivery of Vi polysaccharide conjugate using PLA nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics 2020;152:270-81. [DOI: 10.1016/j.ejpb.2020.05.023] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
46 Hoffman TW, Meek B, Rijkers GT, Grutters JC, van Kessel DA. Pneumococcal Conjugate Vaccination Followed by Pneumococcal Polysaccharide Vaccination in Lung Transplant Candidates and Recipients. Transplant Direct 2020;6:e555. [PMID: 32607421 DOI: 10.1097/TXD.0000000000001003] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Namkoong H, Ishii M, Funatsu Y, Kimizuka Y, Yagi K, Asami T, Asakura T, Suzuki S, Kamo T, Fujiwara H, Tasaka S, Betsuyaku T, Hasegawa N. Theory and strategy for Pneumococcal vaccines in the elderly. Hum Vaccin Immunother 2016;12:336-43. [PMID: 26406267 DOI: 10.1080/21645515.2015.1075678] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
48 Elston JW, Santaniello-Newton A, Meigh JA, Harmer D, Allgar V, Allison T, Richardson G, Meigh R, Palmer SR, Barlow G. Increasing incidence of invasive pneumococcal disease and pneumonia despite improved vaccination uptake: surveillance in Hull and East Yorkshire, UK, 2002-2009. Epidemiol Infect 2012;140:1252-66. [PMID: 22040368 DOI: 10.1017/S0950268811001907] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
49 Macintyre CR, Ridda I, Gao Z, Moa AM, McIntyre PB, Sullivan JS, Jones TR, Hayen A, Lindley RI. A randomized clinical trial of the immunogenicity of 7-valent pneumococcal conjugate vaccine compared to 23-valent polysaccharide vaccine in frail, hospitalized elderly. PLoS One 2014;9:e94578. [PMID: 24760002 DOI: 10.1371/journal.pone.0094578] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
50 Lazarus R, Clutterbuck E, Yu L, Bowman J, Bateman EA, Diggle L, Angus B, Peto TE, Beverley PC, Mant D, Pollard AJ. A Randomized Study Comparing Combined Pneumococcal Conjugate and Polysaccharide Vaccination Schedules in Adults. Clinical Infectious Diseases 2011;52:736-42. [DOI: 10.1093/cid/cir003] [Cited by in Crossref: 77] [Cited by in F6Publishing: 62] [Article Influence: 7.7] [Reference Citation Analysis]
51 Adler H, Ferreira DM, Gordon SB, Rylance J. Pneumococcal Capsular Polysaccharide Immunity in the Elderly. Clin Vaccine Immunol 2017;24:e00004-17. [PMID: 28424198 DOI: 10.1128/CVI.00004-17] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 4.8] [Reference Citation Analysis]
52 Granoff DM, Pelton S, Harrison LH. Meningococcal vaccines. Vaccines. Elsevier; 2013. pp. 388-418. [DOI: 10.1016/b978-1-4557-0090-5.00029-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 1.4] [Reference Citation Analysis]
53 Pace D. Glycoconjugate vaccines. Expert Opinion on Biological Therapy 2012;13:11-33. [DOI: 10.1517/14712598.2012.725718] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 3.9] [Reference Citation Analysis]
54 Tashani M, Jayasinghe S, Harboe ZB, Rashid H, Booy R. Potential carrier priming effect in Australian infants after 7-valent pneumococcal conjugate vaccine introduction. World J Clin Pediatr 2016; 5(3): 311-318 [PMID: 27610348 DOI: 10.5409/wjcp.v5.i3.311] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
55 Ridda I, Musher DM. Is there a potential role for protein-conjugate pneumococcal vaccine in older adults? Australas Med J 2012;5:231-5. [PMID: 22848316 DOI: 10.4066/AMJ.2012.1160] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
56 Daly CA, Spurrier MA, Jennings-Gee JE, Haas KM. B Cell Subsets Differentially Contribute to the T Cell-Independent Memory Pool. J Immunol 2020;205:2362-74. [PMID: 32978280 DOI: 10.4049/jimmunol.1901453] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
57 Dirmesropian S, Wood JG, MacIntyre CR, Newall AT. A review of economic evaluations of 13-valent pneumococcal conjugate vaccine (PCV13) in adults and the elderly. Hum Vaccin Immunother 2015;11:818-25. [PMID: 25933180 DOI: 10.1080/21645515.2015.1011954] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 5.6] [Reference Citation Analysis]
58 Gaillat J. Compared effectiveness of the 7-valent pneumococcal conjugate vaccine in children with the 13-valent vaccine in adults. Med Mal Infect 2013;43:215-21. [PMID: 23769155 DOI: 10.1016/j.medmal.2013.04.005] [Reference Citation Analysis]
59 van Werkhoven CH, Huijts SM. Vaccines to Prevent Pneumococcal Community-Acquired Pneumonia. Clin Chest Med 2018;39:733-52. [PMID: 30390745 DOI: 10.1016/j.ccm.2018.07.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
60 Vila-Corcoles A, Ochoa-Gondar O. Preventing pneumococcal disease in the elderly: recent advances in vaccines and implications for clinical practice. Drugs Aging 2013;30:263-76. [PMID: 23420119 DOI: 10.1007/s40266-013-0060-5] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 4.5] [Reference Citation Analysis]
61 Vadlamudi NK, Parhar K, Altre Malana KL, Kang A, Marra F. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to 23-valent pneumococcal polysaccharide in immunocompetent adults: A systematic review and meta-analysis. Vaccine 2019;37:1021-9. [DOI: 10.1016/j.vaccine.2019.01.014] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 6.5] [Reference Citation Analysis]
62 Kennedy LB, Li Z, Savani BN, Ljungman P. Measuring Immune Response to Commonly Used Vaccinations in Adult Recipients of Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation 2017;23:1614-21. [DOI: 10.1016/j.bbmt.2017.06.006] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
63 Berical AC, Harris D, Dela Cruz CS, Possick JD. Pneumococcal Vaccination Strategies. An Update and Perspective. Ann Am Thorac Soc 2016;13:933-44. [PMID: 27088424 DOI: 10.1513/AnnalsATS.201511-778FR] [Cited by in Crossref: 65] [Cited by in F6Publishing: 33] [Article Influence: 21.7] [Reference Citation Analysis]
64 Bernth-Jensen JM, Søgaard OS. Polysaccharide responsiveness is not biased by prior pneumococcal-conjugate vaccination. PLoS One 2013;8:e75944. [PMID: 24146796 DOI: 10.1371/journal.pone.0075944] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
65 Matera MG, Ora J, Calzetta L, Rogliani P, Cazzola M. Sex differences in COPD management. Expert Rev Clin Pharmacol 2021;14:323-32. [PMID: 33560876 DOI: 10.1080/17512433.2021.1888713] [Reference Citation Analysis]
66 Gattringer R, Winkler H, Roedler S, Jaksch P, Herkner H, Burgmann H. Immunogenicity of a combined schedule of 7-valent pneumococcal conjugate vaccine followed by a 23-valent polysaccharide vaccine in adult recipients of heart or lung transplants. Transpl Infect Dis 2011;13:540-4. [PMID: 21489090 DOI: 10.1111/j.1399-3062.2011.00628.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
67 Froes F, Roche N, Blasi F. Pneumococcal vaccination and chronic respiratory diseases. Int J Chron Obstruct Pulmon Dis 2017;12:3457-68. [PMID: 29255353 DOI: 10.2147/COPD.S140378] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
68 Grabenstein JD, Musher DM. Pneumococcal Polysaccharide Vaccines. Plotkin's Vaccines. Elsevier; 2018. pp. 816-840.e13. [DOI: 10.1016/b978-0-323-35761-6.00046-8] [Cited by in Crossref: 5] [Article Influence: 1.7] [Reference Citation Analysis]
69 Rozenbaum MH, Boersma C, Postma MJ, Hak E. Observed differences in invasive pneumococcal disease epidemiology after routine infant vaccination. Expert Review of Vaccines 2014;10:187-99. [DOI: 10.1586/erv.10.163] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
70 Bahuaud M, Beaudouin-Bazire C, Husson M, Molto A, Launay O, Batteux F, Dougados M. Immunogenicity and persistence of a prime-boost re-vaccination strategy for pneumococcal vaccines in patients with rheumatoid arthritis. Hum Vaccin Immunother 2018;14:1464-70. [PMID: 29432051 DOI: 10.1080/21645515.2018.1438091] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
71 Jackson LA, Gurtman A, van Cleeff M, Frenck RW, Treanor J, Jansen KU, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older. Vaccine 2013;31:3594-602. [PMID: 23688525 DOI: 10.1016/j.vaccine.2013.04.084] [Cited by in Crossref: 100] [Cited by in F6Publishing: 82] [Article Influence: 12.5] [Reference Citation Analysis]
72 Dendle C, Stuart RL, Polkinghorne KR, Balloch A, Kanellis J, Ling J, Kummrow M, Moore C, Thursky K, Buttery J, Mulholland K, Gan PY, Holdsworth S, Mulley WR. Seroresponses and safety of 13-valent pneumococcal conjugate vaccination in kidney transplant recipients. Transpl Infect Dis 2018;20:e12866. [PMID: 29512234 DOI: 10.1111/tid.12866] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
73 Hedberg AL, Pauksens K, Enblad P, Söderberg J, Johansson B, Käyhty H, Sjölin J. Pneumococcal polysaccharide vaccination administered early after neurotrauma or neurosurgery. Vaccine 2017;35:909-15. [PMID: 28069358 DOI: 10.1016/j.vaccine.2016.12.065] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
74 Schaballie H, Wuyts G, Dillaerts D, Frans G, Moens L, Proesmans M, Vermeulen F, De Boeck K, Meyts I, Bossuyt X. Effect of previous vaccination with pneumococcal conjugate vaccine on pneumococcal polysaccharide vaccine antibody responses. Clin Exp Immunol 2016;185:180-9. [PMID: 26939935 DOI: 10.1111/cei.12784] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
75 Iyer AS, Ohtola JA, Westerink MJ. Age-related immune response to pneumococcal polysaccharide vaccination: lessons for the clinic. Expert Review of Vaccines 2014;14:85-97. [DOI: 10.1586/14760584.2015.963058] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
76 Grabenstein JD, Manoff SB. Pneumococcal vaccines in adults: assessing the evolving evidence. Vaccine 2011;29:6149-54. [PMID: 21763386 DOI: 10.1016/j.vaccine.2011.06.116] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
77 Pilishvili T, Bennett NM. Pneumococcal Disease Prevention Among Adults. American Journal of Preventive Medicine 2015;49:S383-90. [DOI: 10.1016/j.amepre.2015.09.008] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
78 Schmid P, Selak S, Keller M, Luhan B, Magyarics Z, Seidel S, Schlick P, Reinisch C, Lingnau K, Nagy E, Grubeck-Loebenstein B. Th17/Th1 biased immunity to the pneumococcal proteins PcsB, StkP and PsaA in adults of different age. Vaccine 2011;29:3982-9. [PMID: 21481328 DOI: 10.1016/j.vaccine.2011.03.081] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
79 Song JY, Lim JH, Lim S, Yong Z, Seo HS. Progress toward a group B streptococcal vaccine. Hum Vaccin Immunother 2018;14:2669-81. [PMID: 29995578 DOI: 10.1080/21645515.2018.1493326] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
80 Marshall H, Nissen M, Richmond P, Shakib S, Jiang Q, Cooper D, Rill D, Baber J, Eiden J, Gruber WC, Jansen KU, Anderson AS, Zito ET, Girgenti D. Safety and immunogenicity of a booster dose of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults: A randomized phase 1 study. J Infect 2016;73:437-54. [PMID: 27519620 DOI: 10.1016/j.jinf.2016.08.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
81 Søgaard OS, Schønheyder HC, Bukh AR, Harboe ZB, Rasmussen TA, Ostergaard L, Lohse N. Pneumococcal conjugate vaccination in persons with HIV: the effect of highly active antiretroviral therapy. AIDS 2010;24:1315-22. [PMID: 20559037 DOI: 10.1097/QAD.0b013e328339fe0b] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 1.9] [Reference Citation Analysis]
82 Fink AL, Klein SL. The evolution of greater humoral immunity in females than males: implications for vaccine efficacy. Curr Opin Physiol 2018;6:16-20. [PMID: 30320243 DOI: 10.1016/j.cophys.2018.03.010] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 9.7] [Reference Citation Analysis]
83 Fink AL, Klein SL. Sex and Gender Impact Immune Responses to Vaccines Among the Elderly. Physiology (Bethesda) 2015;30:408-16. [PMID: 26525340 DOI: 10.1152/physiol.00035.2015] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 8.0] [Reference Citation Analysis]
84 Dendle C, Stuart RL, Mulley WR, Holdsworth SR. Pneumococcal vaccination in adult solid organ transplant recipients: A review of current evidence. Vaccine 2018;36:6253-61. [PMID: 30217523 DOI: 10.1016/j.vaccine.2018.08.069] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 5.7] [Reference Citation Analysis]
85 Crum-Cianflone NF, Huppler Hullsiek K, Roediger M, Ganesan A, Patel S, Landrum ML, Weintrob A, Agan BK, Medina S, Rahkola J, Hale BR, Janoff EN; Infectious Disease Clinical Research Program HIV Working Group. A randomized clinical trial comparing revaccination with pneumococcal conjugate vaccine to polysaccharide vaccine among HIV-infected adults. J Infect Dis 2010;202:1114-25. [PMID: 20795819 DOI: 10.1086/656147] [Cited by in Crossref: 63] [Cited by in F6Publishing: 57] [Article Influence: 5.7] [Reference Citation Analysis]
86 Tashani M, Heron L, Wong M, Rashid H, Booy R. Tetanus-diphtheria-pertussis vaccine may suppress the immune response to subsequent immunization with pneumococcal CRM197-conjugate vaccine (coadministered with quadrivalent meningococcal TT-conjugate vaccine): a randomized, controlled trial⋆. J Travel Med 2017;24. [PMID: 28375507 DOI: 10.1093/jtm/tax006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
87 Ho Y, Brandão AP, de Cunto Brandileone MC, Lopes MH. Immunogenicity and safety of pneumococcal conjugate polysaccharide and free polysaccharide vaccines alone or combined in HIV-infected adults in Brazil. Vaccine 2013;31:4047-53. [DOI: 10.1016/j.vaccine.2013.04.065] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 3.5] [Reference Citation Analysis]
88 Kantsø B, Halkjær SI, Østergaard Thomsen O, Belard E, Gottschalck IB, Jørgensen CS, Krogfelt KA, Slotved HC, Ingels H, Petersen AM. Persistence of antibodies to pneumococcal conjugate vaccine compared to polysaccharide vaccine in patients with Crohn's disease - one year follow up. Infect Dis (Lond) 2019;51:651-8. [PMID: 31290715 DOI: 10.1080/23744235.2019.1638519] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
89 Pilishvili T, Bennett NM Pneumococcal disease prevention among adults: Strategies for the use of pneumococcal vaccines Vaccine. 2015;33:D 60-65. [PMID: 26116257 DOI: 10.1016/j.vaccine.2015.05.102] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 7.8] [Reference Citation Analysis]
90 Baxendale HE, Johnson M, Keating SM, Ashton L, Burbidge P, Woodgate S, Southern J, Miller E, Goldblatt D. Circulating pneumococcal specific plasma and memory B cells in the elderly two years after pneumococcal conjugate versus polysaccharide vaccination. Vaccine 2010;28:6915-22. [PMID: 20708698 DOI: 10.1016/j.vaccine.2010.08.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
91 Wagenvoort G, Vlaminckx B, van Kessel D, Geever R, de Jong B, Grutters J, Bos W, Meek B, Rijkers G. Pneumococcal conjugate vaccination response in patients after community-acquired pneumonia, differences in patients with S. pneumoniae versus other pathogens. Vaccine 2017;35:4886-95. [DOI: 10.1016/j.vaccine.2017.07.088] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
92 Pobre K, Tashani M, Ridda I, Rashid H, Wong M, Booy R. Carrier priming or suppression: understanding carrier priming enhancement of anti-polysaccharide antibody response to conjugate vaccines. Vaccine. 2014;32:1423-1430. [PMID: 24492014 DOI: 10.1016/j.vaccine.2014.01.047] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 7.0] [Reference Citation Analysis]
93 Kobayashi M, Bennett NM, Gierke R, Almendares O, Moore MR, Whitney CG, Pilishvili T. Intervals Between PCV13 and PPSV23 Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2015;64:944-7. [PMID: 26334788 DOI: 10.15585/mmwr.mm6434a4] [Cited by in Crossref: 131] [Cited by in F6Publishing: 103] [Article Influence: 21.8] [Reference Citation Analysis]
94 Metersky ML, Dransfield MT, Jackson LA. Determining the optimal pneumococcal vaccination strategy for adults: is there a role for the pneumococcal conjugate vaccine? Chest 2010;138:486-90. [PMID: 20576729 DOI: 10.1378/chest.10-0738] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
95 Principi N, Esposito S. Prevention of Community-Acquired Pneumonia with Available Pneumococcal Vaccines. Int J Mol Sci 2016;18:E30. [PMID: 28029140 DOI: 10.3390/ijms18010030] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
96 Peñaranda M, Payeras A, Cambra A, Mila J, Riera M; Majorcan Pneumococcal Study Group. Conjugate and polysaccharide pneumococcal vaccines do not improve initial response of the polysaccharide vaccine in HIV-infected adults. AIDS 2010;24:1226-8. [PMID: 20299956 DOI: 10.1097/QAD.0b013e3283389de5] [Cited by in Crossref: 30] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
97 Smith KJ, Wateska AR, Nowalk MP, Raymund M, Lee BY, Zimmerman RK. Modeling of cost effectiveness of pneumococcal conjugate vaccination strategies in U.S. older adults. Am J Prev Med 2013;44:373-81. [PMID: 23498103 DOI: 10.1016/j.amepre.2012.11.035] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 3.8] [Reference Citation Analysis]
98 Chan TC, Hung IF, Luk JK, Shea YF, Chan FH, Woo PC, Chu LW. Prevention of mortality and pneumonia among nursing home older adults by dual pneumococcal and seasonal influenza vaccination during a pandemic caused by novel pandemic influenza A (H1N1). J Am Med Dir Assoc 2012;13:698-703. [PMID: 22722051 DOI: 10.1016/j.jamda.2012.05.009] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
99 Juergens C, de Villiers PJ, Moodley K, Jayawardene D, Jansen KU, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine formulations with and without aluminum phosphate and comparison of the formulation of choice with 23-valent pneumococcal polysaccharide vaccine in elderly adults: a randomized open-label trial. Hum Vaccin Immunother 2014;10:1343-53. [PMID: 24576885 DOI: 10.4161/hv.27998] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
100 Gubbels Bupp MR, Potluri T, Fink AL, Klein SL. The Confluence of Sex Hormones and Aging on Immunity. Front Immunol 2018;9:1269. [PMID: 29915601 DOI: 10.3389/fimmu.2018.01269] [Cited by in Crossref: 82] [Cited by in F6Publishing: 76] [Article Influence: 27.3] [Reference Citation Analysis]
101 Voysey M, Barker CI, Snape MD, Kelly DF, Trück J, Pollard AJ. Sex-dependent immune responses to infant vaccination: an individual participant data meta-analysis of antibody and memory B cells. Vaccine 2016;34:1657-64. [PMID: 26920472 DOI: 10.1016/j.vaccine.2016.02.036] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 5.2] [Reference Citation Analysis]
102 Okapuu JM, Chétrit E, Lefebvre B, Quach C. How many individuals with asthma need to be vaccinated to prevent one case of invasive pneumococcal disease? Can J Infect Dis Med Microbiol 2014;25:147-50. [PMID: 25285110 DOI: 10.1155/2014/510373] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
103 Ciabattini A, Garagnani P, Santoro F, Rappuoli R, Franceschi C, Medaglini D. Shelter from the cytokine storm: pitfalls and prospects in the development of SARS-CoV-2 vaccines for an elderly population. Semin Immunopathol 2020;42:619-34. [PMID: 33159214 DOI: 10.1007/s00281-020-00821-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 13.0] [Reference Citation Analysis]
104 Blumental S, Moïsi JC, Roalfe L, Zancolli M, Johnson M, Burbidge P, Borrow R, Yaro S, Mueller JE, Gessner BD, Goldblatt D. Streptococcus pneumoniae serotype 1 burden in the African meningitis belt: exploration of functionality in specific antibodies. Clin Vaccine Immunol 2015;22:404-12. [PMID: 25651921 DOI: 10.1128/CVI.00758-14] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
105 Mauvais-Jarvis F, Berthold HK, Campesi I, Carrero JJ, Dakal S, Franconi F, Gouni-Berthold I, Heiman ML, Kautzky-Willer A, Klein SL, Murphy A, Regitz-Zagrosek V, Reue K, Rubin JB. Sex- and Gender-Based Pharmacological Response to Drugs. Pharmacol Rev 2021;73:730-62. [PMID: 33653873 DOI: 10.1124/pharmrev.120.000206] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
106 Grabenstein JD, Manoff SB. Pneumococcal polysaccharide 23-valent vaccine: long-term persistence of circulating antibody and immunogenicity and safety after revaccination in adults. Vaccine 2012;30:4435-44. [PMID: 22542818 DOI: 10.1016/j.vaccine.2012.04.052] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 4.3] [Reference Citation Analysis]